The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized, parallel-dose phase 1 study of onapristone (ONA) in patients (pts) with progesterone receptor (PR)-expressing cancers.
Paul H. Cottu
Research Funding - Arno Therapeutics
Andrea Varga
No relevant relationships to disclose
Sylvie Giacchetti
No relevant relationships to disclose
Eric Leblanc
No relevant relationships to disclose
Marc Espie
No relevant relationships to disclose
Anas Gazzah
No relevant relationships to disclose
Veronique Dieras
No relevant relationships to disclose
Catherine Lhomme
No relevant relationships to disclose
Francois Marc Lokiec
Consultant or Advisory Role - Arno Therapeutics
Keyvan Rezai
Consultant or Advisory Role - Arno Therapeutics
Alice Susannah Bexon
Consultant or Advisory Role - Arno Therapeutics
Erard M. Gilles
Employment or Leadership Position - Invivis
Consultant or Advisory Role - Arno Therapeutics
Joseph Bisaha
Employment or Leadership Position - Arno Therapeutics
Stock Ownership - Arno Therapeutics
Alexander Zukiwski
Employment or Leadership Position - Arno Therapeutics
Stock Ownership - Arno Therapeutics
Jacques Bonneterre
Consultant or Advisory Role - Invivis
Honoraria - Invivis